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ABSTRACT
Purpose The Göttingen minipig is a relevant non-rodent spe-
cies for regulatory toxicological studies. Yet, its use with ther-
apeutic antibodies has been limited by the unknown binding
properties of human immunoglobulins (huIgG) to porcine Fc
gamma receptors (poFcγR) influencing safety and efficacy
readouts. Therefore, knowing IgG-FcγR interactions in the
animal model is a prerequisite for the use of minipigs in pre-
clinical safety and efficacy studies with therapeutic antibodies.
Methods Here, we describe the cloning and expression of
poFcγRs and their interactions with free and complexed hu-
man therapeutic IgG1 by surface plasmon resonance and flow
cytometry.
Results We show here that poFcγRIa, poFcγRIIa, and
poFcγRIIb bind huIgG1 antibodies with comparable affinities
as corresponding huFcγRs. Importantly, poFcγRs bind
huIgG immune complexes with high avidity, thus probably
allowing human-like effector functions. However,
poFcγRIIIa binds poIgG1a but not to huIgG1.
Conclusions The lack of binding of poFcγRIIIa to huIgG1
might cause underestimation of FcγRIIIa-mediated efficacy
or toxicity as mediated by porcine natural killer cells.
Therefore, the suitability of minipigs in preclinical studies with
human therapeutic antibodies has to be assessed case by case.
Our results facilitate the use of Göttingen minipigs for assess-
ment of human therapeutic antibodies in preclinical studies.
KEY WORDS antibody effector function . FcγR . Göttingen
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ABBREVIATIONS
ADCC Antibody-dependent cellular cytotoxicity
ADCP Antibody-dependent cellular phagocytosis
FcγR Fc gamma receptor protein
FCGR Fc gamma receptor gene
FcR-γ
chain
Fc receptor common gamma chain
HuCAL Human combinatorial antibody library
IC Immune complex
ITAM Immunoreceptor tyrosine-based activation
motif
NHP Non-human primate
SPR Surface plasmon resonance
INTRODUCTION
Fc gamma Receptors (FcγRs) are a family of gylcoproteins
expressed on the surface of leukocytes. They interact with
the fragment crystallizable (Fc) part of immunoglobulin G
(IgG) antibodies and trigger a variety of effector functions
including antibody-dependent cellular cytotoxicity (ADCC),
antibody-dependent cellular phagocytosis (ADCP), antigen
internalization and presentation, or inflammatory cytokine
release (1). The set of FcγRs of most mammalian species con-
sists of the high affinity FcγRIa (CD64), low affinity FcγRIIa
(CD32a) and FcγRIIIa (CD16), and the inhibitory FcγRIIb
(CD32b) (2). Their cellular distribution and distinct affinities
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towards different IgG subclasses influence immune cell activa-
tion and control their effector functions upon IgG binding.
Many novel therapeutic antibodies are IgG Fc engineered to
alter the FcγR binding in order to achieve enhanced activity
via ADCC or ADCP or to reduce effector function-mediated
toxicity (3,4). Often, antibody effector functions are mediated
upon interactions of low affinity FcγRs with immune com-
plexes (IC). For example, IC formed by bevacizumab binding
to vascular endothelial growth factor (VEGF) can lead to
FcγRIIa-mediated platelet activation (5) and thrombosis in
FcγRIIa transgenic mice (6). Thus, it is very important to
characterize the binding of free- and immune-complexed
IgG to different FcγRs as this can dramatically influence safety
and efficacy.
The porcine species (Sus scrofa) is an increasingly used ani-
mal model for biomedical research. In particular the
Göttingen minipig has gained importance for preclinical safe-
ty and efficacy studies due to its high similarity to the human
(7,8). Also, the regulatory acceptance of the minipig as a rel-
evant animal model for toxicological studies with biothera-
peutics is growing (9). Furthermore, handling, housekeeping,
and breeding of minipigs are much easier and cheaper than of
non-human primates (NHP). So far, the Göttingen minipig
has already been used for immunogenicity studies with inflix-
imab and adalimumab (10). Presently, only few other minipig
studies are performed with therapeutic antibodies (11) due to
lacking knowledge about their pharmacology (12). Therefore,
the importance of an adequate immunological characteriza-
tion of the Göttingen minipig as a non-rodent species is widely
recognized and promoted (13). The evaluation of the interac-
tions of human therapeutic antibodies with porcine FcγRs
(poFcγRs) is a basic requirement for the use of the minipig
in preclinical studies. So far, only functional binding studies of
poFcγRIa and variants of poFcγRIIb to porcine total IgG
have been reported confirming the conserved function of
these receptors in pigs (14,15). We have recently annotated
the complete low affinity FCGR locus of the minipig including
the localization of all poFcγR genes and the description of the
hitherto unknown poFcγRIIa (16). Binding and function of
NHP or mouse FcγRs interacting with human IgG (huIgG)
were studied to assess cross-reactivity and to estimate the
translation potential of this preclinical species (17–19). To
our knowledge, no extensive studies investigating the interac-
tions of huIgG to poFcγRs were performed for any porcine
species. Thus, the lacking knowledge of the binding properties
of huIgG to poFcγRs is still limiting the use of the minipig as a
preclinical species with human therapeutic antibodies.
In the present work we hypothesized minipigs as a useful
alternative for preclinical studies with therapeutic antibodies.
Therefore, we qualitatively characterize the binding of human
therapeutic antibodies to all FcγRs in the minipig.
Furthermore, we assessed the binding of free- and immune-
complexed huIgG1 antibodies to poFcγRs in comparison to
huFcγRs. The data provide first insights into possible effector
functionalities of human immunoglobulins in preclinical stud-
ies in minipigs.
MATERIALS AND METHODS
Recombinant FcγRs and Antibodies
Cloning
Soluble FcγRs were designed as dimeric IgG Fc fusion pro-
teins. Extracellular domains of poFcγRIa (UniProtKB:
Q461Q0), poFcγRIIa (XM_021089520.1; 205Y),
poFcγRIIb (UniProtKB: Q461P7) , poFcγRIIb1
(UniProtKB: B9VVN4), poFcγRIIIa (UniProtKB: Q28942)
as well as huFcγRIa (UniProtKB: P12314), huFcγRIIa
(UniProtKB: P12318 R131), huFcγRIIb (UniProtKB:
P31994), huFcγRIIIa (UniProtKB: P08637 V158) were used.
The sequences were back translated, codon optimized, and
ordered as gene syntheses from GeneArt (Invitrogen).
Subsequently they were cloned into an expression vector con-
taining the signal peptide from mouse Ig heavy chain variable
region, an Avi biotinylation tag (GLNDIFEAQKIEWHE,
Avidity), a His6 tag, and an IgA protease cleavage site
(VVAPP’AP). The vector also contained inert huIgG1
(PGLALA) Fc parts allowing the dimerization of the FcγR
extracellular domains by the expression as Fc fusion proteins
(20). These constructs are referred to as soluble FcγRs
hereafter.
Full-length poFcγRIa (amino acids (aa) 16-346), poFcγRIIa
(205Y; aa 46-274), poFcγRIIb (aa 46-297), poFcγRIIb1 (aa
46-316), and poFcγRIIIa (aa 20-257) contained the human
CD33 signal peptide (MPLLLLLPLLWAGALA) and a
FLAG-tag (DYKDDDDK) at the N-terminus. Full-length
huFcγRs, the human Fc receptor common gamma chain
(FcR-γ chain), and the poFcR-γ chain (UniProtKB:
Q9XSZ6) were designed without the FLAG-tag.
PoIgG1a (GenBank: U03781.1) and poIgG3 (GenBank:
EU372658.1) heavy chain and Ig-kappa light chain (21) con-
stant regions were coupled to the variable regions of the anti-
human epidermal growth factor receptor 2 (HER2) antibody
trastuzumab heavy chain (DrugBank: DB00072; aa 1-120)
and Ig-kappa light chain (DrugBank: DB00072; aa 1-108), re-
spectively. The correct transitions between the variable and
the constant region of both antibodies were confirmed by
molecular modeling. The recombinant antibodies contained
the mouse Ig heavy chain V region 3 signal peptide
(MGWSCIILFLVATATGVHS) and a C-terminal Avi bioti-
nylation tag (GLNDIFEAQKIEWHE, Avidity). The resulting
HER2 specific poIgG constructs are named poIgG1a-HER2
and poIgG3-HER2 hereafter.
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The sequences of all constructs were verified prior to ex-
pression by DNA-sequencing (SequiServe and Microsynth).
Expression
Soluble FcγRs and poIgGs were expressed in human embry-
onic kidney 293F (HEK293F) suspension cells cultured in
shaker flasks (120 rpm, 37°C, 5% CO2, 85% humidity) using
F17 expression medium supplemented with Pluronic and
GlutaMAX (Gibco). Plasmids coding for FcγRs were trans-
fected alone and poIgG heavy chains were co-transfected in
equimolar ratio with plasmids coding for poIg-kappa light
chain. Transient transfection was performed using 293free
(Merck Millipore) premixed with OptiMEM (Gibco) and ex-
pression was enhanced by feeding and addition of valproic
acid. The fed-batch culture was harvested by centrifugation
7 days after transfection and the supernatant was cleared by
filtration.
Full length FcγRs were transiently expressed using the
Expi293 system (Thermofisher). Suspension cells were seeded
in 6 well-plates (120 rpm, 37°C, 5%CO2, 85% humidity) and
co-transfected with porcine or human FcγRs together with the
related FcR-γ chain in an equimolar ratio. The transfected
cells were used 48 h post transfection.
Purification and Analysis
Soluble FcγRs and poIgGs were purified by protein A
(MabSelect SuRe, GE Healthcare) or, in the case of soluble
FcγRIa, by nickel (HisTrap HP, GEHealthcare) affinity chro-
matography using the ÄKTAexplorer 100 Air system (GE
Healthcare). Soluble FcγRs were further purified by prepara-
tive size exclusion chromatography (SEC) using a HiLoad 26/
600 Superdex prep grade column (GE Healthcare) with
20 mM MOPS, 150 mM NaCl, pH 6.0 as a running buffer.
Purified proteins were quantified on a Nanodrop spectro-
photometer (Thermo Scientific) and analyzed under reducing
and non-reducing conditions by capillary gel electrophoresis
using Caliper LabChip (Perkin Elmer) or sodium dodecyl sul-
fate polyacrylamide gel electrophoresis (SDS-PAGE) with
NuPAGE 4–12% Bis-Tris gels in MES buffer followed by
Coomassie staining (SimplyBlue, ThermoFisher) .
Aggregation and molecular weight of the FcγR products were
determined by SEC coupled to Multi-Angle Light Scattering
(MALS) using a Superdex 200 increase 10/300 GL column
(GE Healthcare).
Biotinylation
Soluble poFcγRs were biotinylated via the Avi-tag using the
BirA Biotin-Protein Ligase standard reaction kit (Avidity).
The biotinylation eff icacy was assessed by liquid
chromatography – mass spectrometry (LC-MS) after deglyco-
sylation with PNGase F.
Generation of FcγRIIa and FcγRIIa/b Specific
Antibodies
Purified soluble poFcγRIIa, poFcγRIIb, and poFcγRIII were
sent to BioRad for the generation of bivalent Fab antibodies
dimerized via alkaline phosphatase containing FLAG and
His6 epitope tags (Fab-A-FH). Binders were selected via
phage display method (CysDisplay®) on BioRads Human
Combinatorial Antibody Libraries (HuCAL). PoFcγRIIa/
FcγRIIb cross-reactive HuCAL antibodies were generated
by using poFcγRIIa as an antigen and poFcγRIII as a closely
related antigen to prevent further cross reactivity. Similarly,
poFcγRIIa specific antibodies were generated by using
poFcγRIIb as a closely related antigen. All binders (HuCAL
clones) were tested for their specificity by enzyme-linked im-
munosorbent assay (ELISA) coated with porcine FcγRIIa,
FcγRIIb, and FcγRIII.
Immune Complex Generation
IC were generated by overnight incubation at room temper-
ature of the huIgG1 therapeutic antibody bevacizumab
(149 kDa; Roche) and its dimerized target VEGF165
(38 kDa, BioLegend), as described earlier (5). The antibody
to target ratio of 1:2.5 was generated using 4 μM bevacizu-
mab and 10 μM dimerized VEGF165, whereas the ratio of
1:0.5 was generated using 20 μM bevacizumab and 10 μM
VEGF165, and the ratio of 1:0.1 using 20 μM bevacizumab
and 2 μM VEGF165. IC formation was analyzed by SEC-
MALS using a HPLC system equipped with a Superdex 200
increase 10/300 GL column (GE Healthcare), a TREOS la-
ser light scattering detector, and a T-rEX differential refrac-
tometer (Wyatt Technology).
Flow Cytometry
Phenotyping of FcγR Expression
FcγR expression was assessed in whole blood of a Göttingen
minipig sampled in K2EDTAVacutainer tubes (BD) followed
by treatment with lysing buffer (BD PharmLyse) to remove
erythrocytes. Minipig blood cells were stained with PE-
conjugated antibodies against porcine CD16 (clone G7,
BioRad) or unconjugated HuCAL antibodies against
poFcγRIIa (clone AbD29332.1 BHuCAL32^), FcγRIIa/b
(clone AbD32591.1 BHuCAL91^), or the isotype control
Fab-A-FH (clone AbD05930). The FcγR expression of trans-
fected HEK293F cells was assessed by staining using the
abovementioned antibodies or the PE-conjugated antibodies
against human CD64 (clone 10.1, BioLegend), human CD32
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(clone 3D3, BD), humanCD16 (clone 3G8, BD), or FLAG tag
(clone L5, BioLegend). Unconjugated antibodies were
detected using the secondary PE conjugated goat F(ab’)2
anti-huIgG after washing with FACS buffer (Dulbecco’s
phosphate-buffered saline (DPBS, Gibco) containing 2% bo-
vine serum albumin (Sigma) and 0.1% sodium azide (Sigma)).
After washing with DPBS, dead cells were stained by the
amine reactive Zombie Aqua dye (BioLegend) and the prep-
arations were fixed using BD CellFIX. Events were acquired
on BD LSRFortessa with BD FACSDiva software and data
was further analyzed using FlowJo.
Immune Complex Binding
Binding of IC was assessed by flow cytometry analysis on
whole blood of three Göttingen minipigs. Fresh blood was
collected in Vacutainer tubes coated with K2EDTA (BD)
and subsequently treated with erythrocyte lysis buffer
(PharmLyse, BD) and washed with DPBS. The remaining
blood cells were incubated with the amine reactive dye
Zombie Aqua (BioLegend). After washing with FACS buffer,
the blood cells were incubated in 96 well plates for 1 h at 4°C
with different concentrations of bevacizumab, or
bevacizumab-VEGF165 IC diluted in FACS buffer.
Bevacizumab to VEGF165 ratios of 1:2.5, 1:0.5, and 1:0.1
were used. Unbound antibodies or complexes were removed
by intensive washing with FACS buffer. PE-conjugated sec-
ondary goat F(ab’)2 antibodies against huIg-kappa (Biorad)
were used to detect membrane-bound bevacizumab or IC.
After another two washes with FACS buffer, 100′000 events
were recorded on BD LSRFortessa with and the software BD
FACSDiva. Data was further analyzed using FlowJo.
SPR Experiments
IgG Capturing Setup
The interaction of porcine or human FcγR variants to porcine
or human IgG anti-HER2 was analyzed using surface plas-
mon resonance (SPR) on a Biacore T200 system (GE
Healthcare). First, the extracellular domain of HER2 was
immobilized at pH 4.5 to >3000 response units (RU) on a
CM5 chip using the amine coupling kit (GE Healthcare).
Then, the HER2 specific antibodies trastuzumab (huIgG1,
Roche), poIgG1a-HER2 and poIgG3-HER2 were injected
at a concentration of 100 nM in PBS-P+ buffer (GE
Healthcare) with a pulse of 30s at a flow rate of 10 μl/min
reaching capturing levels of 1000RU. Soluble porcine or hu-
man FcγRs were prepared in solutions of 600, 200 nM and
66.7 nM in PBS-P+ and applied at a flow rate of 30 μl/min
for 90s. The dissociation phase was monitored for 600 s fol-
lowed by regeneration of the surface by a 60s and 20s washing
step with a 10mMGlycine pH 2.1 at a flow rate of 10 μl/min.
All experiments were performed in PBS-P+ pH 7,4 running
buffer.
FcγR Capturing Setup
An alternative setup was used to compare binding of poFcγRs
to free- and immune-complexed huIgG1. Biotinylated soluble
poFcγRs were reversibly captured on a CAP chip using the
standard Biotin CAPture reagent kit (GE Healthcare) at
pH 7.4 PBS-P+. The capturing level of FcγR variants reached
940–2543 RU. Porcine or human biotinylated FcγR variants
were prepared as solution of 200 nM in PBS-P+ and captured
with a pulse of 180 s at a flow rate of 5 μl/min. Subsequently,
human free- or immune-complexed IgG1 were applied at a
concentration of 600, 200 and 66.7 nM in PBS-P+ at a flow
rate of 30 μl/min for 120 s. The dissociation phase was mon-
itored for 600 s. Then, the surface was regenerated by a 120 s
washing step with the regeneration solution for the CAP chip
(GE Healthcare) at a flow rate of 10 μl/min.
SPR Data Analysis
The Biacore T200 software (GEHealthcare) was used to eval-
uate data from SPR experiments and to display binding
curves. Interaction Map was used to separate heterogeneous
binding into its individual 1:1 interactions with different kinet-
ics. For this, data from SPR experiments were imported into
TraceDrawer software (Ridgeview Instruments AB) and fur-
ther processed with the Interaction Map program (Ridgeview
Instruments AB).
RESULTS
Interactions between IgG antibodies and their Fc receptors
are of high complexity. To obtain a thorough characteriza-
tion, we studied poFcγRs as recombinant soluble proteins and
expressed on the cell surface, as well as minipig blood cells that
natively express FcγRs. Interactions of poFcγRs were assessed
with different free- or immune-complexed IgG antibodies and
therapeutics.
Binding of huIgG to poFcγRs
The purpose of this experiment was to show qualitative bind-
ing of poFcγRs to huIgG1, the most commonly used thera-
peutic human antibody isotype, by SPR. A highly sensitive
assay is needed to detect weak interactions because low affinity
FcγRs (FcγRIIa, FcγRIIb, and FcγRIIIa) generally interact
only weakly with free IgG. Therefore, soluble porcine and
human FcγRs were designed and used here as dimers of
FcγR extracellular domains expressed as inert Fc fusion pro-
teins. The dimeric structure provides an avidity effect and
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increases the molecular mass leading to higher sensitivity and
therefore allowing a qualitative binding analysis (20).
Transient expression in HEK293F cells and subsequent puri-
fication yielded soluble FcγRs of >98% purity as determined
by capillary gel electrophoresis or SDS-PAGE (not shown).
PoFcγRIIb is exclusively composed of dimers, whereas
poFcγRIa, poFcγRIIa, and poFcγRIIIa preparations addi-
tionally contained 32%, 74%, and 77% aggregates, respec-
tively, even after SEC purification (not shown). N-linked gly-
cosylation of FcγRs and Fc fusion was effective in HEK293F
cells as observed by PNGase F digestion followed by SDS-
PAGE (Fig. S1).
For the SPR binding analysis, the recombinant HER2 an-
tigen was coated on a CM5 sensor chip and then allowed to
capture trastuzumab, a HER2 specific huIgG1 therapeutic
antibody, or HER2 specific poIgGs (Fig. 1a). To this purpose,
the two most abundant isotypes in porcine blood, IgG1a and
IgG3 (22), were recombinantly expressed with HER2 speci-
ficity, and named poIgG1a-HER2 and poIgG3-HER2, re-
spectively. The soluble poFcγRs were then allowed to bind
human and porcine HER2-specific IgG (Fig. 1a).
Figure 1b shows the maximum responses observed with
huIgG1 in interaction with 600 nM of porcine and human
FcγRs. From this analysis we conclude that trastuzumab binds
to most poFcγRs in a similar magnitude as to huFcγRs (Fig.
1b). A closer analysis of the sensorgrams generated using three
concentrations of the soluble FcγRs permits a ranking of the
binding strength among the different FcγRs (Fig. 1c). The
sensorgrams show the response (RU) during association of
the soluble FcγRs to antigen bound IgG until the steady state
in the first 100 s followed by their dissociation. Among
poFcγRs, we identified poFcγRIa as the strongest binder for
huIgG1 based on the quicker association and the slower dis-
sociation, followed by poFcγRIIa. PoFcγRIIb is the weakest
binder with the quickest dissociation whereas poFcγRIIIa did
not bind huIgG1. However, the functionality of poFcγRIIIa
was demonstrated through its binding to poIgG1 (Fig. 1c). A
similar binding pattern was observed for huFcγRs with
huFcγRIa as the strongest binder of huIgG1 followed by
huFcγRIIa, FcγRIIb, and huFcγRIIIa in a similar range.
Comparing the orthologous porcine and human FcγRs,
huIgG1 bound stronger to poFcγRIIa and poFcγRIIb but
weaker to poFcγRIa and poFcγRIIIa as compared to the hu-
man orthologue (Fig. 1c). For all poFcγRs, except
poFcγRIIIa, we observed a similar binding pattern of
huIgG1 and poIgG1a-HER2. In contrast, poIgG3-HER2
showed only weak interactions to poFcγRIa and poFcγRIIa
and no binding to poFcγRIIb and poFcγRIIIa. Vice versa,
huFcγRs did not notably bind to poIgGs (Fig. 1c). In sum,
we found that poIgG1 binds to poFcγRIa > poFcγRIIa >
poFcγRIIb and poFcγRIIIa in a similar range, whereas
huIgG1 binds to poFcγRIa > poFcγRIIa > poFcγRIIb > >
poFcγRIIIa.
The shape of the sensorgrams in Fig. 1c suggested complex
multiple interactions contributing to IgG-FcγR bindings.
Such heterogeneous interactions probably originate from dif-
ferent qualities of the individual FcγRs based on their integrity
and the presence of aggregates. To assess the contribution of
quality issues leading to heterogeneous interactions, we also
analyzed the huIgG1 binding data using the Interaction Map
method (Fig. 1d). It allows the decomposition of time-resolved
binding curves into separate interactions with unique combi-
nations of association rates ka [M
−1, s−1] and dissociation rates
kd [s
−1], contributing to the total binding (23). Therefore, the
Interaction Map analysis allows addressing the heterogeneity
of IgG-FcγR interactions. The resulting on-off plots display
single interactions by their dissociation (log(kd), x-axis) and
association (log(ka), y-axis) values colored according to their
contribution to the total binding (Fig. 1d). Because no inter-
action of trastuzumab was observed with poFcγRIIIa, this
data could not be analyzed by Interaction Map. For the other
FcγRs, this analysis disclosed multiple interactions involved in
the binding of huIgG1 to poFcγRIa, poFcγRIIa, and
huFcγRIIIa (Fig. 1d). Interestingly, the FcγRs with the most
obvious multivalent binding properties were the preparations
with the highest proportion of aggregates. Therefore, one spot
originates from the bivalent functional binding, whereas the
other spot reflects the binding to aggregates contained in the
preparation. Because aggregates reformed after SEC purifica-
tion, it was not possible to identify which interaction was re-
sponsible for the functional binding. The correct binding ki-
netics of these FcγRs must be a mixture of the observed inter-
actions. Therefore, we refrain from reporting affinities based
on one 1:1 kinetic. Additionally, it was shown by other authors
that IgG-FcγR interactions do not depend on only one 1:1
kinetic and are strongly influenced by the experimental setup
and other factors, such as FcγR glycosylation (24).
In addition to poFcγRIIb, another isoform named
poFcγRIIb1 has been reported having a 19 amino acid in-
frame insertion in the cytoplasmic domain. Apart from the
signal sequence, these variants also differ by one polymor-
phism in the extracellular domain 1 and two polymorphisms
in the extracellular domain 2 (the latter are marked in yellow
in Fig. S2) (25). We directly compared these two polymorphic
variants in SPR regarding binding to porcine or human IgG
and found no differences in IgG isotype selectivity and negli-
gible stronger binding of the poFcγRIIb1 variant (Fig. S3).
Binding of huIgG1 to poFcγRs on Cells
Next, we addressed binding of free huIgG1 to poFcγRs in a
more biological system with transfected HEK293F cells
expressing surface-anchored FcγRs. Due to the lack of avail-
able antibodies specific for poFcγRs, we also generated phage-
display based recombinant antibodies with specificity for
poFcγRs using the HuCAL technology. The specificity of
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these HuCAL antibodies was also assessed using cell surface-
anchored FcγRs.
Full length poFcγRs with extracellular FLAG tags encoded
at the N-terminus were transiently expressed on HEK293F
cells. However, full-length huFcγRs were expressed without
FLAG tags. The data shown in Fig. 2a demonstrate expres-
sion of all porcine and human FcγRs on the cell surface of
HEK293F cells. The expression of huFcγRs and of
poFcγRIIIa was characterized via commercial FcγR-specific
antibodies whereas a FLAG tag specific antibody was used to
characterize the expression of all poFcγRs. The expression of
poFcγRIIa was further demonstrated with the antibody clone
HuCAL32 that binds specifically to this FcγR in contrast to
the antibody clone HuCAL91 that is cross-reactive to the
closely similar FcγRIIb (Fig. 2a).
Binding to FcγRs expressed on HEK293F cells was then
assessed using different concentrations of bevacizumab, a
huIgG1 anti-VEGF therapeutic antibody displaying similar
SPR binding to poFcγR as trastuzumab (not shown). Cell
bound bevacizumab was detected via flow cytometry using
goat F(ab’)2 anti-huIg-kappa secondary antibody. The results
show a concentration-dependent binding of bevacizumab to
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Fig. 1 SPR binding analysis of soluble FcγRs to IgG. (a) Scheme depicting the assay setup. First, extracellular domains of HER2 were coated on a CM5 sensor
chip. Then, HER2 specific human (blue structures) and porcine (orange structures) antibodies were captured on different flow cells. Their interactions with soluble
porcine or human FcγRs were measured. The drawing shows low affinity FcγRs with two and the high affinity FcγRIa with three extracellular domains (oval
shapes). (b) The graph shows the maximum response of 600 nM porcine (black bars) and human (grey bars) FcγRs obtained with huIgG1. (c) Real-time
sensorgrams from SPR analysis. Interaction of IgG to poFcγRs is shown in the upper row and to huFcγRs in the lower row whereas the respective FcγRs are
named above. Binding of 600 nM soluble FcγRs to trastuzumab (huIgG1, blue line), poIgG1a-HER2 (orange line), and poIgG3-HER2 (yellow line) is shown. Only
the highest concentration of the titration with 600, 200, and 66.7 nM of soluble FcγRs is shown for clarity. (d) Interaction Map analysis resulting from trastuzumab
binding to all concentrations of porcine and human FcγRs is shown in the upper and lower row, respectively. The binding is separated in several parallel
interactions with unique kinetics, as displayed by spots on a graph with kd on the x-axis and ka on the y-axis. The heat map is a measure of the contribution from
red= high to blue= low of each interaction to the total binding. No interaction was detected with poFcγRIIIa; therefore, it could not be analyzed (N/A).
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porcine (except for poFcγRIIIa) and human FcγRs (Fig. 2b).
From these data we conclude that surface-anchored
poFcγRIa, IIa and IIb, but not poFcγRIIIa can bind by free
huIgG1.
Binding of huIgG1 Immune Complexes to poFcγRs
Human low affinity FcγRs mediate their functions rather via
interaction with IC in contrast to free IgG (26). The increase
in avidity compensates for the low affinity and allows stable
binding to the IC ultimately leading to activation of the FcγRs.
In order to assess binding of poFcγRs to huIgG1 IC we per-
formed SPR experiments with pre-formed IC of bevacizumab
and its dimeric target antigen VEGF.
To generate physiological IC, bevacizumab was co-
incubated with VEGF and the resulting complexes were stud-
ied by SEC-MALS. The stoichiometric ratio of one antibody
together with an excess of five VEGF dimers resulted in large
IC without remaining free IgG where the majority of com-
plexes is composed of three or more antibodies (Fig. 3a). For
the measurement of their binding profiles in comparison to
free IgG, all poFcγRs were biotinylated and coated on the
sensor chip (Fig. 3b). For every FcγR, two different capturing
densities were assayed. The densities of FcγRIa (940RU),
FcγRIIa (1020RU), and FcγRIIb (2543RU) were found to
give best results probably reflecting their different affinities
to huIgG1. We, however, did not achieve sufficient biotinyla-
tion of poFcγRIIIa to increase its capturing density above
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Fig. 2 Binding of bevacizumab (huIgG1) to FcγRs transiently expressed on HEK293F cells. (a) HEK293F cells expressing the indicated porcine (left panel) and
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54RU, and was therefore excluded from the experiment.
Subsequently, 600, 200, and 66.7 nM of free huIgG1 or IC
formed with the same amount of huIgG1 were used to assess
the binding strength (Fig. 3b).
The sensorgrams in Fig. 3c show a strong increase in the
maximum response and a more stable interaction with IC
compared to free huIgG1 in all poFcγRs. We again analyzed
the SPR binding data with the Interaction Map method (Fig.
3d) first, because the observed maximum response largely
depends on the size of the bound complex and second, be-
cause we expect avidity based heterogeneous IC-FcγR
interactions. Using this setup, we observed two to three inter-
actions contributing to the binding of poFcγRs to free
huIgG1, probably resulting from partial activity of the soluble
FcγRs (Fig. 3d). The contribution of all interactions shifted
towards lower kd and higher ka values and ultimately towards
a stronger binding comparing free bevacizumab to IC.
Additionally, Fig. 3d shows a shift of the individual interac-
tions towards a higher affinity. For poFcγRIa, for example,
the higher affinity interaction shifts the center of the spot to a
5x longer half-life (shift towards lower kd) as seen in Fig. 3d
and evaluated by the interaction map software, a 10x quicker
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association (shift towards higher ka), and therefore a 100x
enhanced affinity (KD = kd/ka) comparing free huIgG1 to IC.
Additionally, its contribution increases from 31% to 65%.
On the other hand, the low affinity interaction decreases its
contribution from 50% to 16% (Fig. 3d, left plots). For
poFcγRIIa and poFcγRIIb the changes in affinity from free
huIgG1 to IC are comparable to those for poFcγRIa. This
data clearly demonstrates a stronger and more stable interac-
tion of huIgG1 IC with poFcγRs than with free huIgG1 based
on avidity effects. IC binding is a prerequisite for effector
functions triggered by huIgG in minipigs.
Binding of huIgG1 IC to Minipig Blood Cells
Next, we studied interactions of free huIgG1 (bevacizumab) to
blood cells of Göttingen minipigs that natively express
poFcγRs. Free huIgG1 and different preparations of IC were
titrated and co-incubated with minipig whole blood for 1 h at
4°C in FACS buffer containing sodium azide to prevent inter-
nalization. Bound antibodies or IC were stained using goat
F(ab’)2 anti-huIg-kappa secondary antibody and analyzed by
flow cytometry. The different blood cell subsets were gated
from forward and side scatter (FSC/SSC) of viable single cells
without including specific cell surface markers due to limited
availability of specific antibodies, fluorochromes, and cross-re-
activity. The gating strategy and identity of the different cell
types of the minipig blood is shown in Fig. S4. The FcγR
expression in the respective minipig blood cells was assessed
in separate stainings and shown in Fig. 4a. PoFcγRIIa (stained
by HuCAL32) was found to be expressed on platelets and a
sub-population of eosinophils. The poFcγRIIa/b cross-reactive
antibody (HuCAL91) additionally stained a large proportion of
monocytes that are thus thought to express poFcγRIIb.
Monocytes, neutrophils, and eosinophils all express
poFcγRIIIa. Furthermore, small lymphocyte subsets, such as
B cells and NK cells are known to express poFcγRIIb and
poFcγRIIIa, respectively and monocytes are known to express
poFcγRIa (16,27). The poFcγRIa expression beyond lympho-
cytes and monocytes is largely unknown and can thus not be
excluded on platelets, neutrophils, and eosinophils. Histograms
in Fig. 4b show the binding of 0.1 μg/ml free huIgG1 and the
same amount of huIgG1 complexed using different ratios of
VEGF165 to the different minipig blood cell subsets. The an-
tibody (bevacizumab, Bev) to target (VEGF) ratio of 1:2.5
yielded the largest IC without free huIgG1 whereas IC gener-
ated in the ratio of 1:0.5 and 1:0.1 were smaller and contained
more free huIgG1 (Fig. S5). Here, we observed that large IC
showed enhanced binding to all platelets and most monocytes
versus smaller IC and free huIgG1. Furthermore, large IC
resulted in the strongest shift of neutrophils and eosinophils,
even though the MFI was lower than in platelets and mono-
cytes. A small subpopulation of lymphocytes also bound large
IC better than small IC and free huIgG1 (Fig. 4b). As in the
histograms, it is apparent from the titration of all IC prepara-
tions in the blood of three Göttingen minipigs that free- and
immune-complexed huIgG1 exhibit the strongest binding to
platelets, followed by monocytes, eosinophils, neutrophils and
lastly lymphocytes (Fig. 4c). The titration shows that in partic-
ular the largest IC strongly bind to poFcγR-expressing cell
types at the lowest concentrations translating to the highest
affinity. Vice versa, preparations with limited VEGF165 or
without VEGF165 (huIgG1 alone) require higher concentra-
tions to bind to poFcγR-expressing cell types, translating to
lower affinities. VEGF165 did not bind to minipig blood cells
at the concentration used to generate the largest IC (ratio 1:2.5)
containing 10 μg/ml huIgG1. The strongest differences be-
tween free-and immune-complexed huIgG1 were observed in
platelets and monocytes. Neutrophils and eosinophils also
bound IC stronger than free huIgG1, however the maximum
percentage of positive cells in these cell types were lower and
the individual differences were more pronounced leading to a
higher standard deviation (Fig. 4c).
DISCUSSION
The use of the Göttingen minipig in preclinical studies with
therapeutic antibodies is limited by the lack of knowledge on
the expected pharmacology for the translatability of
corresponding findings to the human. The pharmacology of
antibodies with active Fc parts often depends on effector
mechanisms mediated by interaction with FcγRs. The aim
of this study was to assess the binding properties of huIgG1
therapeutic antibodies to poFcγRs which is a prerequisite for
the consideration of the minipig for preclinical safety and ef-
ficacy studies with therapeutic antibodies.
The present study demonstrates that poFcγRs bind human
therapeutic antibodies of the IgG1 isotype. The binding prop-
erties of the poFcγRIa, poFcγRIIa, and poFcγRIIb closely
resemble those of the human orthologues albeit some differ-
ences were identified. Importantly, poFcγRIIIa was shown not
to bind huIgG1 antibodies. Similar to huFcγRs, all poFcγRs
except poFcγRIIIa were shown to bind IC composed of
huIgG1 with a higher affinity than free huIgG1. Especially,
monocytes, eosinophils, platelets and a subset of lymphocytes
of minipig blood showed enhanced binding to human IC.
The poFcγRIa was cloned by Zhang, Qiao (15) and
shown to bind poIgG. Here we also demonstrate that
poFcγRIa, similar to its human orthologue, strongly binds
huIgG1 (28). The high affinity interaction of huFcγRIa is
supposed to be mediated by a hydrophobic pocket for
Leu235 within the Fc part of huIgG (29). The same pocket
was also identified in poFcγRIa supporting its high affinity
for huIgG1 (Fig. S2). Nevertheless, we found differences
between the two species in residues forming H bonds
(Lys128, Ala143 in Fig. S2). This could explain the weaker
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binding of huIgG1 to poFcγRIa compared to huFcγRIa.
The observed difference concerning the heterogeneity of
interactions probably results from avidity effects caused
by FcγR aggregation. PoFcγRIa is, like its human ortho-
logue, expressed on monocytes in peripheral blood of min-
ipigs (16). A fraction of minipig monocytes binds huIgG1
IC already at low concentrations, possibly mediated by
poFcγRIa, although poFcγRIIb and poFcγRIIIa cannot
be excluded since these FcγRs are also expressed on mono-
cytes. The enhanced binding of complexed versus free
huIgG1 to poFcγRIa was confirmed by SPR. Notably,
we did not observe a strong staining with free huIgG1 as
it could be expected for binding to poFcγRIa. A gradual
dissociation of free IgG1 from huFcγRIa is believed to
allow capturing small IC or sparsely opsonized large com-
plexes (30). Our results suggest a similar role of poFcγRIa
by the observation of the strong IC binding (Fig. 3c and d)
and weak staining of poFcγRIa expressing monocytes with
low concentrations of free huIgG (Fig. 4b).
FcγRIIa is known as a low affinity receptor signaling
through an integrated intracellular immunoreceptor
tyrosine-based activation motif (ITAM) in the human.
However, orthologues to FcγRIIa in the mouse, cattle and
pig, for example, are lacking this integrated ITAM and re-
quire FcR γ-chain interactions for signaling (16,31). In terms
of binding, we found that FcγRIIa of both species bind
huIgG1 (Fig. 1). Conserved tryptophan residues Trp104 and
Trp127 forming the BTrp sandwich^ of FcγRs that interacts
with Pro329 of IgG Fc parts could enable such cross-species
interactions (Fig. S2) (32). Interestingly, trastuzumab bound to
poFcγRIIa with an increased stability compared to huFcγRIIa
(Fig. 1). HEK293F cells expressing porcine and human
FcγRIIa showed similarities in binding properties to bevaci-
zumab as observed by the concentration-dependent increase
of binding (Fig. 2b). The differences in background and the
intensity of the positive population possibly originate from the
lower expression of poFcγRIIa compared to huFcγRIIa on
HEK293F cells (Fig. 2). A high avidity binding of IC to
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poFcγRIIa was observed by SPR as described for human low
affinity receptors (Fig. 3c and d) (33). This was also reflected in
the strong binding of IC to minipig platelets expressing highest
levels of FcγRIIa (Fig. 4a). Yet, platelets were also the strongest
binders of free bevacizumab. This could be explained by the
increased affinity of poFcγRIIa in relation to huFcγRIIa. The
increased affinity could further lead to an enhanced sensitivity
of the minipig for FcγRIIa binding and ultimately to an over-
prediction of FcγRIIa-mediated toxicities in preclinical stud-
ies. Lau, Gunnarsen (34) observed platelet aggregation and
toxicities in domestic pigs treated with mouse IgG2b anti-
porcine CD14 (clone MIL2) possibly due to FcγR activation
and complement binding. A recombinant huIgG2/4 anti-
porcine CD14 antibody (rMIL2) however, did not induce ag-
gregation probably due to abolished FcγR or complement
binding in pigs.
The inhibitory low affinity FcγRIIb is mainly expressed on
human B cells, dendritic cells (DC), and tissue macrophages
and is an important regulator of immune responses (1). Here,
we report enhanced binding of poFcγRIIb to trastuzumab in
comparison with huFcγRIIb (Fig. 1). The Interaction Map
analysis shows a homogeneous interaction for the porcine
and human FcγRIIb. Therefore, we conclude that the three
times increased affinity is not assay dependent. This finding is
also in concordance with Macaca nemestrina FcγRIIb showing
enhanced huIgG1 binding (32). FcγRIIb of macaques and
cyno have residues His131 at the location of the huFcγRIIa
His131Arg polymorphism and Met132 nearby. These resi-
dues were shown to account for the increased binding while
huFcγRIIb has Arg131 and Ser132 in these positions. In
poFcγRIIb, however, we identified residues Tyr and Val at
the corresponding positions probably influencing the binding
in another way (Fig. S2). Triggering of the inhibitory
huFcγRIIb in macrophages and dendritic cells can counteract
the effects mediated by activating FcγRs (35). Enhanced bind-
ing of huIgG1 to poFcγRIIb could therefore enhance the
threshold for cell activation and result in a more tolerogenic
milieu in inflamed tissue, thus leading to an overestimated
efficiency of immunosuppressive therapeutic antibodies in
minipigs. Simultaneously, treatment with therapeutic
huIgG1 antibodies could lead to enhanced risk for pneumo-
coccal peritonitis while reducing pathological immune stimu-
lation due to reduced reactivity of macrophages (36,37).
Furthermore, FcγRIIb expressed on B cells plays an important
role in maintenance of peripheral tolerance (38). Thus, the
stronger binding of huIgG1 antibodies to poFcγRIIb on B
cells could lead to enhanced tolerance and hence to underes-
timation of immunogenicity concerns.
From all studied receptors, the most pronounced differen-
ces between minipig and human were observed for FcγRIIIa.
In humans, FcγRIIIa is a low affinity activating receptor bind-
ing huIgG1 IC with high avidity and mediating important
functions such as ADCC of monocytes and natural killer
(NK) cells. PoFcγRIIIa, in contrast, binds neither free- nor
immune-complexed huIgG1, and poIgG1a only with low af-
finity. This binding pattern was observed with recombinant
soluble poFcγRIIIa in SPR assays with trastuzumab and with
HEK293F cells and neutrophils expressing poFcγRIIIa in in-
teraction with bevacizumab (Figs. 1, 2 and 4). The nature of
the poor binding properties of poFcγRIIIa is unknown.
However, we cannot exclude binding to other porcine or hu-
man IgG subclasses. Similarly, it is known that huIgG isotypes
bind differently to mouse FcγRs than mouse IgG isotypes (39).
The strong surface expression of FcγRIIIa on porcine mono-
cytes, eosinophils, neutrophils and NK cells suggests impor-
tant roles for effector functions involving these cell types.
Possibly, poFcγRIIIa mediates such functions in with
poIgG1a IC or in association with other poIgG isotypes.
Indeed, 11 Ig heavy constant gamma (IGHG) genes coding
for six different IgG subclasses exist in pigs whose specific
functions are still unknown (40).
Interestingly, an influenza virus study in landrace cross
pigs by Morgan, Holzer (41) reported a lack of efficacy of a
hemagglutinin-specific huIgG1 antibody that was expected
to reduce the viral load via FcγR-interaction. The mech-
anistic investigation by flow cytometry revealed no signif-
icant binding of free- and immune-complexed huIgG1 to
porcine peripheral blood mononuclear cells including lym-
phocytes and monocytes, even though a slight elevation of
positive cells was observed with IC. However, the results
from the present study show that large IC, but not free
huIgG1 below 10 μg/ml bind to monocytes and weakly
to a lymphocyte subset (Fig. 4). These results are difficult
to compare to our study due to the unknown huIgG1
concentration, unreported gating, and uncharacterized
IC in the publication. Importantly, Morgan, Holzer (41)
have shown that the therapeutic huIgG1 antibody does
not elicit ADCC by porcine PBMCs and thus concluded
a lacking interaction between huIgG1 and all poFcγRs.
The present study confirms the lacking interaction be-
tween huIgG1 and poFcγRIIIa, that is an important me-
diator of ADCC in monocytes and NK cells. Nevertheless,
we found that huIgG1 antibodies bind to all other
poFcγRs. Even though no reduction of the viral load was
observed due to lacking ADCC, the said study reported
reduced gross pathology (decreased surface of lung lesion)
with the hemagglutinin antibody and the huIgG1 control.
As proposed before, this finding could be explained by the
strong binding huIgG1 to poFcγRIIb and the expression
of this receptor on porcine monocytes. The inhibitory
function of poFcγRIIb could thus lead to a monocyte-
mediated anti-inflammatory effect in interaction with
huIgG1 complexes and therefore to reduced tissue dam-
age. On the other hand, the inhibition could be another
reason for the unaffected viral load in addition to the lack
of NK cell-mediated ADCC.
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CONCLUSION
In this study, we identified similarities and differences be-
tween porcine and human FcγRs regarding binding to
huIgG. Taken together, we inferred proper FcγR-
mediated effector functions upon treatment of minipigs
with human therapeutic antibodies. Due to the similar
binding properties of FcγRIa, FcγRIIa, and FcγRIIb we
suggest the minipig as a valuable species for assessment of
IC-mediated toxicities such as bevacizumab induced
platelet activation. The limitations of the minipig relate
to the failure of poFcγRIIIa to bind huIgG1 antibodies to
mediate effects such as ADCC as demonstrated by the
influenza study in pigs with a huIgG1 antibody discussed
before (41). Because minipig NK cells express poFcγRIIIa
as the only FcγR, we conclude that this cell type cannot
mediate ADCC and other effector functions via huIgG1.
However, monocyte-mediated effector functions cannot
be excluded with huIgG1 because this cell type expresses
other FcγRs in addition to poFcγRIIIa. Nevertheless, a
reduced or lacking efficacy of huIgG1 antibodies is
expected in the minipig. Furthermore, as in most animal
species for preclinical studies, also FcγRIIIb-mediated
effects of neutrophils, such as acute infusion reactions,
cannot be predicted in the minipig due to the unique
expression of FcγRIIIb in the human (42). However, the
minipig is well suited for pharmacodynamic (PD) studies
with therapeutic antibodies as comparable binding
strengths of huIgGs were observed to the neonatal Fc
receptor (FcRn) between minipigs and humans (43).
Nevertheless, it has to be mentioned that the selection of
the Göttingen minipig for preclinical studies is dependent
on the pharmacological activity of the therapeutic anti-
body and thus cross-reactivity with the porcine target is
required. Furthermore, in vitro functional studies and ac-
tivity assays should be performed to assess the pharmacol-
ogy of a particular therapeutic antibody prior to the se-
lection of the minipig for preclinical studies.
Here we have described for the first time the cloning and
expression of poFcγRIIa, as well as the binding pattern of
human therapeutic antibodies to all poFcγRs. The
Interaction Map analysis used in this study is a tool to under-
stand complex binding mechanisms in vitro and highlights the
complexity of FcγR-IgG interactions. Furthermore, it relativ-
izes statements about FcγR affinities in interaction with IgG.
Additionally, many novel special formats of therapeutic anti-
bodies are often Fc engineered for altered FcγR binding in-
fluencing their mode of action. The binding properties of
these novel antibody formats to minipig FcγRs can thus not
easily be predicted from our data and will have to be estab-
lished in a case by case evaluation. The experimental systems
described here provide a suitable basis of tools for such
evaluation.
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